Premium
Striatal Serotonin Receptors and Dopamine Release
Author(s) -
Balcioglu Aygul,
Wurtman Richard J
Publication year - 2000
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1046/j.1471-4159.2000.0750886.x
Subject(s) - ketanserin , serotonin , dopamine , basal ganglia , chemistry , receptor , endocrinology , 5 ht receptor , medicine , dopamine receptor d2 , antagonist , pharmacology , biology , central nervous system
To the Editors: Lucas and Spampinato (2000) described our study (Wurtman and Balcioglu, 1998) as showing that ketanserin, a preferential serotonin 5-HT2A antagonist, failed to modify the enhancement of striatal dopamine (DA) efflux induced by intrastriatal infusion of 1-(4-iodo-2,5-dimethoxyphenyl)2-aminopropane (DOI). We, in fact, stated the following: “Local application of 1 mM DOI increased DA release to 250 6 90% of control values. Pretreatment with ketanserin blocked this increase and also reduced the basal release of DA to 27 6 5% of control values.” Thus our observations did not support Lucas and Spampinato’s conclusion that 5-HT2A receptors are not involved in mediating the enhancement of DA release by DOI. Aygul Balcioglu Richard J. Wurtman Department of Brain and Cognitive Sciences Massachusetts Institute of Technology Cambridge, MA, U.S.A.